Review



gdf15  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems gdf15
    Gdf15, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gdf15/product/R&D Systems
    Average 93 stars, based on 15 article reviews
    gdf15 - by Bioz Stars, 2026-03
    93/100 stars

    Images



    Similar Products

    93
    MedChemExpress recombinant murine gdf15 protein
    Recombinant Murine Gdf15 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant murine gdf15 protein/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    recombinant murine gdf15 protein - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    93
    R&D Systems gdf15
    Gdf15, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gdf15/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    gdf15 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    Novo Nordisk recombinant human gdf15
    a ) Pathway analysis from RNA-sequencing of gWAT following 1-hr epinephrine treatment. n = 6 per group. b ) Heat map showing ligand-encoded genes from RNA-sequencing of gWAT following 1-hr epinephrine treatment. n = 6 per group. c ) Circulating <t>GDF15</t> from age-matched male (saline n = 9 , epinephrine n = 9 ) and female mice (saline n = 10 , epinephrine n = 11 ) following 1-hr epinephrine with fold-change relative to baseline levels (inset). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with post-hoc test and Tukey’s correction and unpaired two-tail t-test, respectively. d ) Time-course of circulating GDF15 post-saline (RT n = 5 , TN n = 4 ) or epinephrine (RT n = 5 , TN n = 5 ) in mice housed at room temperature (RT ~ 22 °C) or thermoneutrality (TN ~ 29 °C) for 4 weeks. n = 4-5/group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA at each time point. e ) Serum epinephrine in control ( n = 9 mice), 1-hr post IP epinephrine ( n = 7 ), and 4-hr physical restraint ( n = 8 ). Data presented as mean ± s.e.m. with p-values calculated using 1-way ANOVA with post-hoc test and Tukey’s correction.
    Recombinant Human Gdf15, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human gdf15/product/Novo Nordisk
    Average 90 stars, based on 1 article reviews
    recombinant human gdf15 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    PeproTech recombinant human gdf15/mic-1 protein (cho-derived)
    a ) Pathway analysis from RNA-sequencing of gWAT following 1-hr epinephrine treatment. n = 6 per group. b ) Heat map showing ligand-encoded genes from RNA-sequencing of gWAT following 1-hr epinephrine treatment. n = 6 per group. c ) Circulating <t>GDF15</t> from age-matched male (saline n = 9 , epinephrine n = 9 ) and female mice (saline n = 10 , epinephrine n = 11 ) following 1-hr epinephrine with fold-change relative to baseline levels (inset). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with post-hoc test and Tukey’s correction and unpaired two-tail t-test, respectively. d ) Time-course of circulating GDF15 post-saline (RT n = 5 , TN n = 4 ) or epinephrine (RT n = 5 , TN n = 5 ) in mice housed at room temperature (RT ~ 22 °C) or thermoneutrality (TN ~ 29 °C) for 4 weeks. n = 4-5/group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA at each time point. e ) Serum epinephrine in control ( n = 9 mice), 1-hr post IP epinephrine ( n = 7 ), and 4-hr physical restraint ( n = 8 ). Data presented as mean ± s.e.m. with p-values calculated using 1-way ANOVA with post-hoc test and Tukey’s correction.
    Recombinant Human Gdf15/Mic 1 Protein (Cho Derived), supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human gdf15/mic-1 protein (cho-derived)/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant human gdf15/mic-1 protein (cho-derived) - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    PeproTech recombinant human gdf15
    a ) Pathway analysis from RNA-sequencing of gWAT following 1-hr epinephrine treatment. n = 6 per group. b ) Heat map showing ligand-encoded genes from RNA-sequencing of gWAT following 1-hr epinephrine treatment. n = 6 per group. c ) Circulating <t>GDF15</t> from age-matched male (saline n = 9 , epinephrine n = 9 ) and female mice (saline n = 10 , epinephrine n = 11 ) following 1-hr epinephrine with fold-change relative to baseline levels (inset). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with post-hoc test and Tukey’s correction and unpaired two-tail t-test, respectively. d ) Time-course of circulating GDF15 post-saline (RT n = 5 , TN n = 4 ) or epinephrine (RT n = 5 , TN n = 5 ) in mice housed at room temperature (RT ~ 22 °C) or thermoneutrality (TN ~ 29 °C) for 4 weeks. n = 4-5/group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA at each time point. e ) Serum epinephrine in control ( n = 9 mice), 1-hr post IP epinephrine ( n = 7 ), and 4-hr physical restraint ( n = 8 ). Data presented as mean ± s.e.m. with p-values calculated using 1-way ANOVA with post-hoc test and Tukey’s correction.
    Recombinant Human Gdf15, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human gdf15/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant human gdf15 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    93
    R&D Systems recombinant gdf15 protein
    a ) Pathway analysis from RNA-sequencing of gWAT following 1-hr epinephrine treatment. n = 6 per group. b ) Heat map showing ligand-encoded genes from RNA-sequencing of gWAT following 1-hr epinephrine treatment. n = 6 per group. c ) Circulating <t>GDF15</t> from age-matched male (saline n = 9 , epinephrine n = 9 ) and female mice (saline n = 10 , epinephrine n = 11 ) following 1-hr epinephrine with fold-change relative to baseline levels (inset). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with post-hoc test and Tukey’s correction and unpaired two-tail t-test, respectively. d ) Time-course of circulating GDF15 post-saline (RT n = 5 , TN n = 4 ) or epinephrine (RT n = 5 , TN n = 5 ) in mice housed at room temperature (RT ~ 22 °C) or thermoneutrality (TN ~ 29 °C) for 4 weeks. n = 4-5/group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA at each time point. e ) Serum epinephrine in control ( n = 9 mice), 1-hr post IP epinephrine ( n = 7 ), and 4-hr physical restraint ( n = 8 ). Data presented as mean ± s.e.m. with p-values calculated using 1-way ANOVA with post-hoc test and Tukey’s correction.
    Recombinant Gdf15 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant gdf15 protein/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    recombinant gdf15 protein - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    93
    Boster Bio gdf15
    Characteristics of obesity subjects according to MASLD and MetS
    Gdf15, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gdf15/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    gdf15 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    93
    R&D Systems recombinant gdf15 957 gd
    a , b , Change in body weight ( a ) and food intake ( b ) of 26–28-week-old male DIO C57BL/6J mice following 7 days of treatment with the indicated dose of N -acetyltaurine (NAT; i.p.). For saline versus N -acetyltaurine (15 mg per kg per day), P = 5.95 × 10 –4 ; for saline versus N -acetyltaurine (50 mg per kg per day), P = 6.3 × 10 –4 . N = 5 per group for vehicle, 1 and 5 mg per kg per day; N = 6 per group for 15 and 50 mg per kg per day. c , d , Change in body weight ( c ) and food intake ( d ) of 19–21-week-old male DIO C57BL/6J mice following treatment with the indicated metabolite at a dose of 15 mg per kg per day (i.p.). N = 5 per group. e – g , Western blots with anti-PTER (top) and anti-tubulin (bottom) antibodies ( e ), N -acetyltaurine hydrolysis activity ( f ) and tissue N -acetyltaurine levels ( g ) from cortex (Cort.), hypothalamus (Hyp.) and brainstem (BS) of WT mice and Pter KO mice. For WT versus Pter KO brainstem, P = 6.65 × 10 –4 . N = 6 per group for f and g . h , Change in 24-h food intake of 6-month-old male DIO mice treated with a single dose of <t>GDF15</t> (0.1 mg kg –1 , i.p.) in the presence of anti-GFRAL antibody (10 mg kg –1 , i.p.) or IgG control antibody (10 mg kg –1 , i.p.). N = 5 per group. i , j , Change in body weight ( i ) and cumulative food intake ( j ) of 16-week-old male DIO mice following saline or N -acetyltaurine (15 mg per kg per day, i.p.) treatment and with IgG or anti-GFRAL antibody co-treatment (10 mg kg –1 , i.p., once every 3 days). N = 10 per group. Data are shown as the mean ± s.e.m. For e , the loading control was performed on the same blot. In a – d and f – h , P values were calculated from two-tailed unpaired t -tests and were not corrected for multiple comparisons. In i and j , P values were calculated from two-way ANOVA with post hoc Sidak’s multiple comparisons test. All experiments were performed once.
    Recombinant Gdf15 957 Gd, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant gdf15 957 gd/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    recombinant gdf15 957 gd - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    Image Search Results


    a ) Pathway analysis from RNA-sequencing of gWAT following 1-hr epinephrine treatment. n = 6 per group. b ) Heat map showing ligand-encoded genes from RNA-sequencing of gWAT following 1-hr epinephrine treatment. n = 6 per group. c ) Circulating GDF15 from age-matched male (saline n = 9 , epinephrine n = 9 ) and female mice (saline n = 10 , epinephrine n = 11 ) following 1-hr epinephrine with fold-change relative to baseline levels (inset). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with post-hoc test and Tukey’s correction and unpaired two-tail t-test, respectively. d ) Time-course of circulating GDF15 post-saline (RT n = 5 , TN n = 4 ) or epinephrine (RT n = 5 , TN n = 5 ) in mice housed at room temperature (RT ~ 22 °C) or thermoneutrality (TN ~ 29 °C) for 4 weeks. n = 4-5/group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA at each time point. e ) Serum epinephrine in control ( n = 9 mice), 1-hr post IP epinephrine ( n = 7 ), and 4-hr physical restraint ( n = 8 ). Data presented as mean ± s.e.m. with p-values calculated using 1-way ANOVA with post-hoc test and Tukey’s correction.

    Journal: Nature Metabolism

    Article Title: GDF15 links adipose tissue lipolysis with anxiety

    doi: 10.1038/s42255-025-01264-3

    Figure Lengend Snippet: a ) Pathway analysis from RNA-sequencing of gWAT following 1-hr epinephrine treatment. n = 6 per group. b ) Heat map showing ligand-encoded genes from RNA-sequencing of gWAT following 1-hr epinephrine treatment. n = 6 per group. c ) Circulating GDF15 from age-matched male (saline n = 9 , epinephrine n = 9 ) and female mice (saline n = 10 , epinephrine n = 11 ) following 1-hr epinephrine with fold-change relative to baseline levels (inset). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with post-hoc test and Tukey’s correction and unpaired two-tail t-test, respectively. d ) Time-course of circulating GDF15 post-saline (RT n = 5 , TN n = 4 ) or epinephrine (RT n = 5 , TN n = 5 ) in mice housed at room temperature (RT ~ 22 °C) or thermoneutrality (TN ~ 29 °C) for 4 weeks. n = 4-5/group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA at each time point. e ) Serum epinephrine in control ( n = 9 mice), 1-hr post IP epinephrine ( n = 7 ), and 4-hr physical restraint ( n = 8 ). Data presented as mean ± s.e.m. with p-values calculated using 1-way ANOVA with post-hoc test and Tukey’s correction.

    Article Snippet: Recombinant human GDF15 (5 nM kg −1 ; Novo Nordisk) or vehicle was injected IP at ~09:00 (ref. ).

    Techniques: RNA Sequencing, Saline, Control

    a , Schematic of acute vehicle and adrenaline treatment and analyses. b , Top: time in the centre and total distance travelled during an open-field test 1 h following treatment with adrenaline ( n = 14) or saline ( n = 13). Bottom: representative images of movements of individual mice. Data are presented as mean ± s.e.m. with P values calculated using an unpaired two-tailed t test. c , Principal component analysis of gWAT samples from saline-treated ( n = 6) and adrenaline-treated ( n = 6) mice using VST data from DESeq2. d , Gene-concept network diagram indicating the corresponding enriched Gene Ontology (GO) terms according to DEGs between saline-treated ( n = 6) and adrenaline-treated ( n = 6) gWAT. e , Volcano plot showing DEGs identified between saline- and adrenaline-treated gWAT. The P -adj was calculated using the Benjamini–Hochberg method. FC, fold change. f , Time course of circulating GDF15 before and after adrenaline ( n = 5 mice) or saline ( n = 3) treatment. Data are presented as mean ± s.e.m. with P values calculated using an unpaired two-tailed t test. g , Tissue screen of Gdf15 in mice 1 h after adrenaline ( n = 8) or saline ( n = 9) treatment. Data are expressed relative to the saline-treated liver. Data are presented as mean ± s.e.m. with P values calculated using an unpaired two-tailed t test. ND, not detected; BAT, brown adipose tissue. h , Serum GDF15 levels in mice from the following groups: maintained in their home cage ( n = 5), with cage change for 30 min ( n = 8), group-housed ( n = 6) or single-housed for 3 days ( n = 8). Data are presented as mean ± s.e.m. with P values calculated using an unpaired two-tailed t test. i , Schematic of an acute restraint test in WT and Adrb1 , Adrb2 and Adrb3 triple knockout (BR −/− ) mice. j , Serum GDF15 levels in WT and BR −/− mice following 4 h of tube restraint (WT n = 10, BR −/− n = 14) or the control condition (WT n = 9, BR −/− n = 12). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. k , gWAT Gdf15 expression levels in WT and BR −/− mice following 4 h of tube restraint (WT n = 6, BR −/− n = 7) or the control condition (WT n = 5, BR −/− n = 6). a.u., arbitrary units. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction.

    Journal: Nature Metabolism

    Article Title: GDF15 links adipose tissue lipolysis with anxiety

    doi: 10.1038/s42255-025-01264-3

    Figure Lengend Snippet: a , Schematic of acute vehicle and adrenaline treatment and analyses. b , Top: time in the centre and total distance travelled during an open-field test 1 h following treatment with adrenaline ( n = 14) or saline ( n = 13). Bottom: representative images of movements of individual mice. Data are presented as mean ± s.e.m. with P values calculated using an unpaired two-tailed t test. c , Principal component analysis of gWAT samples from saline-treated ( n = 6) and adrenaline-treated ( n = 6) mice using VST data from DESeq2. d , Gene-concept network diagram indicating the corresponding enriched Gene Ontology (GO) terms according to DEGs between saline-treated ( n = 6) and adrenaline-treated ( n = 6) gWAT. e , Volcano plot showing DEGs identified between saline- and adrenaline-treated gWAT. The P -adj was calculated using the Benjamini–Hochberg method. FC, fold change. f , Time course of circulating GDF15 before and after adrenaline ( n = 5 mice) or saline ( n = 3) treatment. Data are presented as mean ± s.e.m. with P values calculated using an unpaired two-tailed t test. g , Tissue screen of Gdf15 in mice 1 h after adrenaline ( n = 8) or saline ( n = 9) treatment. Data are expressed relative to the saline-treated liver. Data are presented as mean ± s.e.m. with P values calculated using an unpaired two-tailed t test. ND, not detected; BAT, brown adipose tissue. h , Serum GDF15 levels in mice from the following groups: maintained in their home cage ( n = 5), with cage change for 30 min ( n = 8), group-housed ( n = 6) or single-housed for 3 days ( n = 8). Data are presented as mean ± s.e.m. with P values calculated using an unpaired two-tailed t test. i , Schematic of an acute restraint test in WT and Adrb1 , Adrb2 and Adrb3 triple knockout (BR −/− ) mice. j , Serum GDF15 levels in WT and BR −/− mice following 4 h of tube restraint (WT n = 10, BR −/− n = 14) or the control condition (WT n = 9, BR −/− n = 12). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. k , gWAT Gdf15 expression levels in WT and BR −/− mice following 4 h of tube restraint (WT n = 6, BR −/− n = 7) or the control condition (WT n = 5, BR −/− n = 6). a.u., arbitrary units. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction.

    Article Snippet: Recombinant human GDF15 (5 nM kg −1 ; Novo Nordisk) or vehicle was injected IP at ~09:00 (ref. ).

    Techniques: Saline, Two Tailed Test, Triple Knockout, Control, Expressing

    a ) Serum GDF15 levels in children with overweight and obesity with ( n = 23 ) or without ( n = 24 ) diagnosis of anxiety. Data presented as mean ± s.e.m. with p-values calculated using unpaired two-tail t-test. b ) Scatter plot of the SNP-effect on GDF15 and single nucleotide polymorphism (SNP)-effect on nervous anxiety tension or depression in humans by using two sample Mendelian Randomization (2SMR). Data presented as mean ± error bars indicate 95% CI, n = 407,746 participants in UK Biobank. MR analysis was performed by using Simple median method, MR weighted mode estimator, Weighted median method, MR Egger regression, Inverse variance weighted methods. c ) Single SNP analysis of GDF15 on anxiety and depression in humans, Data presented as mean ± error bars indicate 95% CI, n = 407,746 participants in UK Biobank.

    Journal: Nature Metabolism

    Article Title: GDF15 links adipose tissue lipolysis with anxiety

    doi: 10.1038/s42255-025-01264-3

    Figure Lengend Snippet: a ) Serum GDF15 levels in children with overweight and obesity with ( n = 23 ) or without ( n = 24 ) diagnosis of anxiety. Data presented as mean ± s.e.m. with p-values calculated using unpaired two-tail t-test. b ) Scatter plot of the SNP-effect on GDF15 and single nucleotide polymorphism (SNP)-effect on nervous anxiety tension or depression in humans by using two sample Mendelian Randomization (2SMR). Data presented as mean ± error bars indicate 95% CI, n = 407,746 participants in UK Biobank. MR analysis was performed by using Simple median method, MR weighted mode estimator, Weighted median method, MR Egger regression, Inverse variance weighted methods. c ) Single SNP analysis of GDF15 on anxiety and depression in humans, Data presented as mean ± error bars indicate 95% CI, n = 407,746 participants in UK Biobank.

    Article Snippet: Recombinant human GDF15 (5 nM kg −1 ; Novo Nordisk) or vehicle was injected IP at ~09:00 (ref. ).

    Techniques: Biomarker Discovery

    a ) Serum GDF15 from WT and β-adrenergic receptor knockout (BR -/- ) mice following 2-hr LPS treatment (WT n = 6 , BR -/- n = 6 ) or control (WT n = 6 , BR -/- n = 8 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA. b ) Blood glucose from WT and BR -/- mice following 2-hr LPS treatment (WT n = 6 , BR -/- n = 6 ) or control (WT n = 6 , BR -/- n = 8 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA.

    Journal: Nature Metabolism

    Article Title: GDF15 links adipose tissue lipolysis with anxiety

    doi: 10.1038/s42255-025-01264-3

    Figure Lengend Snippet: a ) Serum GDF15 from WT and β-adrenergic receptor knockout (BR -/- ) mice following 2-hr LPS treatment (WT n = 6 , BR -/- n = 6 ) or control (WT n = 6 , BR -/- n = 8 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA. b ) Blood glucose from WT and BR -/- mice following 2-hr LPS treatment (WT n = 6 , BR -/- n = 6 ) or control (WT n = 6 , BR -/- n = 8 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA.

    Article Snippet: Recombinant human GDF15 (5 nM kg −1 ; Novo Nordisk) or vehicle was injected IP at ~09:00 (ref. ).

    Techniques: Knock-Out, Control

    a – g , gWAT Atgl expression ( a ), serum nonesterified fatty acids (NEFA) ( b ), gWAT Atf4 expression ( c ), gWAT Chop expression ( d ), gWAT Ppargc1a expression ( e ), gWAT phosphorylated PKA substrates with a representative Western blot image ( f ) and gWAT Gdf15 expression in AdATGL flox/flox (saline n = 5, CL n = 7) and AdATGL −/− (saline n = 7, CL n = 6) mice ( g ). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. h , Circulating GDF15 levels in AdATGL flox/flox (saline n = 5, CL n = 7) and AdATGL −/− (saline n = 7, CL n = 6) mice. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. i , Top: serum GDF15 after 1 h of CL and cilostamide cotreatment in mice ( n = 6 per group). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. Bottom: schematic of the acute restraint test in AdATGL flox/flox and AdATGL −/− mice. j , Serum glycerol levels in AdATGL flox/flox mice (control n = 6, restraint n = 6) and AdATGL −/− mice (control n = 13, restraint n = 11) following restraint. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. k , Left: serum GDF15 in AdATGL flox/flox mice (control n = 6, restraint n = 6) and AdATGL −/− mice (control n = 13, restraint n = 11). Right: graph showing the fold change. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA (left) and an unpaired two-tailed t test (right). l , Glycerol levels in medium from white adipocytes treated with CL and/or ATGListatin ( n = 9 per group; individual data points from three independent experiments). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. m , GDF15 levels in medium from white adipocytes treated with CL and/or ATGListatin ( n = 9 per group; individual data points from three independent experiments). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA. n , Gdf15 expression in adipocytes and SVF from gWAT ( n = 6) and iWAT ( n = 5) of mice. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA. o , Gdf15 expression in adipocytes and SVF from gWAT 1 h after saline ( n = 7) or adrenaline ( n = 9) treatment. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction.

    Journal: Nature Metabolism

    Article Title: GDF15 links adipose tissue lipolysis with anxiety

    doi: 10.1038/s42255-025-01264-3

    Figure Lengend Snippet: a – g , gWAT Atgl expression ( a ), serum nonesterified fatty acids (NEFA) ( b ), gWAT Atf4 expression ( c ), gWAT Chop expression ( d ), gWAT Ppargc1a expression ( e ), gWAT phosphorylated PKA substrates with a representative Western blot image ( f ) and gWAT Gdf15 expression in AdATGL flox/flox (saline n = 5, CL n = 7) and AdATGL −/− (saline n = 7, CL n = 6) mice ( g ). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. h , Circulating GDF15 levels in AdATGL flox/flox (saline n = 5, CL n = 7) and AdATGL −/− (saline n = 7, CL n = 6) mice. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. i , Top: serum GDF15 after 1 h of CL and cilostamide cotreatment in mice ( n = 6 per group). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. Bottom: schematic of the acute restraint test in AdATGL flox/flox and AdATGL −/− mice. j , Serum glycerol levels in AdATGL flox/flox mice (control n = 6, restraint n = 6) and AdATGL −/− mice (control n = 13, restraint n = 11) following restraint. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. k , Left: serum GDF15 in AdATGL flox/flox mice (control n = 6, restraint n = 6) and AdATGL −/− mice (control n = 13, restraint n = 11). Right: graph showing the fold change. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA (left) and an unpaired two-tailed t test (right). l , Glycerol levels in medium from white adipocytes treated with CL and/or ATGListatin ( n = 9 per group; individual data points from three independent experiments). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. m , GDF15 levels in medium from white adipocytes treated with CL and/or ATGListatin ( n = 9 per group; individual data points from three independent experiments). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA. n , Gdf15 expression in adipocytes and SVF from gWAT ( n = 6) and iWAT ( n = 5) of mice. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA. o , Gdf15 expression in adipocytes and SVF from gWAT 1 h after saline ( n = 7) or adrenaline ( n = 9) treatment. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction.

    Article Snippet: Recombinant human GDF15 (5 nM kg −1 ; Novo Nordisk) or vehicle was injected IP at ~09:00 (ref. ).

    Techniques: Expressing, Western Blot, Saline, Control, Two Tailed Test

    a ) Fgf21 expression in mouse adipocyte and SVF from gWAT post-saline ( n = 4 per group) or epinephrine ( n = 5 per group). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with post-hoc test and Tukey’s correction. b ) Leptin expression in mouse adipocyte and SVF from gWAT post-saline ( n = 3 per group) or epinephrine ( n = 4 per group). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA. c ) t-SNE plot of Lin- stromal vascular cells from gWAT of control mice and mice treated with CL for 3 days. Clustering identified 6 major cell types/states. Clusters are highlighted in different colors. The data set was queried for cells expressing Gdf15 . Heatmap shows expression of Gdf15 and other cell-identifying factors in the various identified cell populations. d ) F480/Adgre1 expression in mouse F480+ and F480- fractions of SVF from gWAT 1-hr post-epinephrine treatment (0.5 mg/kg). Data presented as mean ± s.e.m. with n = 3 per group. p-values calculated using 2-way ANOVA. e ) Arg1 and Nos2 expression in bone marrow-derived macrophages (BMDMs) polarized to either M1-like or M2-like. n = 6 per group. Individual data points represent duplicates from 3 independent experiments. Data presented as mean ± s.e.m. with p-values calculated using 1-way ANOVA with post-hoc test and Tukey’s correction. f ) GDF15 levels in media from BMDMs polarized to either M1-like or M2-like for 24-hrs. n = 3 per group. Individual data points represent triplicates from 3 independent experiments. Data presented as mean ± s.e.m. with p-values calculated using 1-way ANOVA with post-hoc test and Tukey’s correction. g ) GDF15 levels in media from M2-like BMDMs treated with epinephrine (1 μM) or tunicamycin (5 ng/mL) for 24-hrs. n = 3 per group. Individual data points represent triplicates from 3 independent experiments. Data presented as mean ± s.e.m. with p-values calculated using 1-way ANOVA with post-hoc test and Tukey’s correction. h ) Volcano plot showing fatty acid transporters identified between M1- and M2-like macrophage populations from scRNA-seq data.

    Journal: Nature Metabolism

    Article Title: GDF15 links adipose tissue lipolysis with anxiety

    doi: 10.1038/s42255-025-01264-3

    Figure Lengend Snippet: a ) Fgf21 expression in mouse adipocyte and SVF from gWAT post-saline ( n = 4 per group) or epinephrine ( n = 5 per group). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with post-hoc test and Tukey’s correction. b ) Leptin expression in mouse adipocyte and SVF from gWAT post-saline ( n = 3 per group) or epinephrine ( n = 4 per group). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA. c ) t-SNE plot of Lin- stromal vascular cells from gWAT of control mice and mice treated with CL for 3 days. Clustering identified 6 major cell types/states. Clusters are highlighted in different colors. The data set was queried for cells expressing Gdf15 . Heatmap shows expression of Gdf15 and other cell-identifying factors in the various identified cell populations. d ) F480/Adgre1 expression in mouse F480+ and F480- fractions of SVF from gWAT 1-hr post-epinephrine treatment (0.5 mg/kg). Data presented as mean ± s.e.m. with n = 3 per group. p-values calculated using 2-way ANOVA. e ) Arg1 and Nos2 expression in bone marrow-derived macrophages (BMDMs) polarized to either M1-like or M2-like. n = 6 per group. Individual data points represent duplicates from 3 independent experiments. Data presented as mean ± s.e.m. with p-values calculated using 1-way ANOVA with post-hoc test and Tukey’s correction. f ) GDF15 levels in media from BMDMs polarized to either M1-like or M2-like for 24-hrs. n = 3 per group. Individual data points represent triplicates from 3 independent experiments. Data presented as mean ± s.e.m. with p-values calculated using 1-way ANOVA with post-hoc test and Tukey’s correction. g ) GDF15 levels in media from M2-like BMDMs treated with epinephrine (1 μM) or tunicamycin (5 ng/mL) for 24-hrs. n = 3 per group. Individual data points represent triplicates from 3 independent experiments. Data presented as mean ± s.e.m. with p-values calculated using 1-way ANOVA with post-hoc test and Tukey’s correction. h ) Volcano plot showing fatty acid transporters identified between M1- and M2-like macrophage populations from scRNA-seq data.

    Article Snippet: Recombinant human GDF15 (5 nM kg −1 ; Novo Nordisk) or vehicle was injected IP at ~09:00 (ref. ).

    Techniques: Expressing, Saline, Control, Derivative Assay

    a , Top: t -distributed stochastic neighbour embedding plot of stromal vascular cells from gWAT of mice treated with CL for 3 days. Clustering identified ten major cell types or states. cDCs, conventional dendritic cells; NKT, natural killer T; NK, natural killer; VECs, vascular endothelial cells. Bottom: data were queried for cell clusters expressing Gdf15 . exp., expression. b , Heat map showing the expression of Gdf15 and other cell-identifying factors in the various cell populations identified in scRNA-seq data. c , Data were queried to determine Gdf15 expression in the identified macrophage populations. d , Median normalized average Gdf15 expression in the M2-like, M1-like and macrophage populations from CL-treated mouse scRNA-seq data. The box-and-whisker plot is defined by the median (centre line) with the first quartile (Q1, lower line), third quartile (Q3, upper line), maximum (Q1 − 1.5 × interquartile range) and minimum (Q3 + 1.5 × interquartile range). Whiskers: 1.5 × (Q3 − Q1). P values were calculated using a one-way ANOVA with Benjamini–Hochberg correction for multiple tests. e , Gdf15 expression in mouse F4/80 + and F4/80 − fractions ( n = 3 per group). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. f , Experimental schematic of the isolation, activation and treatment of BMDMs. g , GDF15 levels in medium from BMDMs treated with fatty acids ( n = 3) or tunicamycin ( n = 2). Individual data points represent triplicates from three independent experiments. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. h , Gdf15 expression in BMDMs treated with fatty acids ( n = 3) or tunicamycin ( n = 2). Data points represent triplicates from three independent experiments. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. i , GO enrichment analysis of M1- and M2-like macrophage populations from scRNA-seq data. The P -adj was calculated using the Benjamini–Hochberg method. j , GDF15 levels in medium from M2-like BMDMs treated with rosiglitazone (Rosi) or T0070907 (T007) ( n = 9 per group). Individual data points represent triplicates from three independent experiments. Data are presented as mean ± s.e.m. with P values calculated using a one-way ANOVA with post hoc testing and Tukey’s correction. k , GDF15 levels in medium from M2-like BMDMs treated with palmitate (Palm) or T0070907 (T007) ( n = 9 per group). Individual data points represent triplicates from three independent experiments. Data are presented as mean ± s.e.m. with P values calculated using a one-way ANOVA with post hoc testing and Tukey’s correction. f created using BioRender.com .

    Journal: Nature Metabolism

    Article Title: GDF15 links adipose tissue lipolysis with anxiety

    doi: 10.1038/s42255-025-01264-3

    Figure Lengend Snippet: a , Top: t -distributed stochastic neighbour embedding plot of stromal vascular cells from gWAT of mice treated with CL for 3 days. Clustering identified ten major cell types or states. cDCs, conventional dendritic cells; NKT, natural killer T; NK, natural killer; VECs, vascular endothelial cells. Bottom: data were queried for cell clusters expressing Gdf15 . exp., expression. b , Heat map showing the expression of Gdf15 and other cell-identifying factors in the various cell populations identified in scRNA-seq data. c , Data were queried to determine Gdf15 expression in the identified macrophage populations. d , Median normalized average Gdf15 expression in the M2-like, M1-like and macrophage populations from CL-treated mouse scRNA-seq data. The box-and-whisker plot is defined by the median (centre line) with the first quartile (Q1, lower line), third quartile (Q3, upper line), maximum (Q1 − 1.5 × interquartile range) and minimum (Q3 + 1.5 × interquartile range). Whiskers: 1.5 × (Q3 − Q1). P values were calculated using a one-way ANOVA with Benjamini–Hochberg correction for multiple tests. e , Gdf15 expression in mouse F4/80 + and F4/80 − fractions ( n = 3 per group). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. f , Experimental schematic of the isolation, activation and treatment of BMDMs. g , GDF15 levels in medium from BMDMs treated with fatty acids ( n = 3) or tunicamycin ( n = 2). Individual data points represent triplicates from three independent experiments. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. h , Gdf15 expression in BMDMs treated with fatty acids ( n = 3) or tunicamycin ( n = 2). Data points represent triplicates from three independent experiments. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. i , GO enrichment analysis of M1- and M2-like macrophage populations from scRNA-seq data. The P -adj was calculated using the Benjamini–Hochberg method. j , GDF15 levels in medium from M2-like BMDMs treated with rosiglitazone (Rosi) or T0070907 (T007) ( n = 9 per group). Individual data points represent triplicates from three independent experiments. Data are presented as mean ± s.e.m. with P values calculated using a one-way ANOVA with post hoc testing and Tukey’s correction. k , GDF15 levels in medium from M2-like BMDMs treated with palmitate (Palm) or T0070907 (T007) ( n = 9 per group). Individual data points represent triplicates from three independent experiments. Data are presented as mean ± s.e.m. with P values calculated using a one-way ANOVA with post hoc testing and Tukey’s correction. f created using BioRender.com .

    Article Snippet: Recombinant human GDF15 (5 nM kg −1 ; Novo Nordisk) or vehicle was injected IP at ~09:00 (ref. ).

    Techniques: Expressing, Whisker Assay, Isolation, Activation Assay

    a , Time in the centre during the open-field test following treatment with saline (WT n = 5 mice, Gfral −/− n = 6) or adrenaline (WT n = 6, Gfral −/− n = 6). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. b , Top: total movement during the open-field test following treatment with saline (WT n = 5, Gfral −/− n = 6) or adrenaline (WT n = 6, Gfral −/− n = 6). Bottom: representative images of movements of individual mice. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. c , Left: schematic of the acute restraint test. Right: time in the centre during the open-field test following 4 h of tube restraint (WT n = 11 mice, Gfral −/− n = 8) or the control condition (WT n = 10, Gfral −/− n = 9). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. d , Total distance travelled during the open-field test following restraint (WT n = 11 mice, Gfral −/− n = 9) or the control condition (WT n = 10, Gfral −/− n = 9). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA. e , Top: quantification of c-Fos + cells in the bed nucleus of the stria terminalis (BNST), central amygdala (CeA) and paraventricular nucleus of the hypothalamus (PVN) of mice 90 min following treatment with IP injected GDF15. Bottom: representative pictures of the staining ( n = 4 per group). Data are presented as mean ± s.e.m. with P values calculated using an unpaired two-tailed t test. Scale bar, 200 µm. 3V, third ventricle; ac, anterior commissure; BLA, basolateral amygdala; LV, lateral ventricle. f , Serum corticosterone following restraint (WT n = 9 mice, Gfral −/− n = 8) or the control condition (WT n = 9, Gfral −/− n = 8). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. g , Serum GDF15 after treatment with CRH (WT n = 5 mice, Gfral −/− n = 6) or vehicle (WT n = 3, Gfral −/− n = 4). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. h , Schematic summary of the mechanism of GDF15-mediated anxiety-like behaviour. h created using BioRender.com .

    Journal: Nature Metabolism

    Article Title: GDF15 links adipose tissue lipolysis with anxiety

    doi: 10.1038/s42255-025-01264-3

    Figure Lengend Snippet: a , Time in the centre during the open-field test following treatment with saline (WT n = 5 mice, Gfral −/− n = 6) or adrenaline (WT n = 6, Gfral −/− n = 6). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. b , Top: total movement during the open-field test following treatment with saline (WT n = 5, Gfral −/− n = 6) or adrenaline (WT n = 6, Gfral −/− n = 6). Bottom: representative images of movements of individual mice. Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. c , Left: schematic of the acute restraint test. Right: time in the centre during the open-field test following 4 h of tube restraint (WT n = 11 mice, Gfral −/− n = 8) or the control condition (WT n = 10, Gfral −/− n = 9). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. d , Total distance travelled during the open-field test following restraint (WT n = 11 mice, Gfral −/− n = 9) or the control condition (WT n = 10, Gfral −/− n = 9). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA. e , Top: quantification of c-Fos + cells in the bed nucleus of the stria terminalis (BNST), central amygdala (CeA) and paraventricular nucleus of the hypothalamus (PVN) of mice 90 min following treatment with IP injected GDF15. Bottom: representative pictures of the staining ( n = 4 per group). Data are presented as mean ± s.e.m. with P values calculated using an unpaired two-tailed t test. Scale bar, 200 µm. 3V, third ventricle; ac, anterior commissure; BLA, basolateral amygdala; LV, lateral ventricle. f , Serum corticosterone following restraint (WT n = 9 mice, Gfral −/− n = 8) or the control condition (WT n = 9, Gfral −/− n = 8). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. g , Serum GDF15 after treatment with CRH (WT n = 5 mice, Gfral −/− n = 6) or vehicle (WT n = 3, Gfral −/− n = 4). Data are presented as mean ± s.e.m. with P values calculated using a two-way ANOVA with post hoc testing and Tukey’s correction. h , Schematic summary of the mechanism of GDF15-mediated anxiety-like behaviour. h created using BioRender.com .

    Article Snippet: Recombinant human GDF15 (5 nM kg −1 ; Novo Nordisk) or vehicle was injected IP at ~09:00 (ref. ).

    Techniques: Saline, Control, Injection, Staining, Two Tailed Test

    a ) Non-ambulatory movements, b ) Total physical activity, c ) Total food intake, d ) respiratory exchange ratio (RER), e ) Energy expenditure in WT (saline n = 4 , epinephrine n = 4 ) and Gfral -/- mice (saline n = 4 , epinephrine n = 4 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with post-hoc test and Tukey’s correction. f ) Chow intake (18-hrs) following tube restraint in WT (control n = 7 , restraint n = 7 ) and Gfral -/- mice (control n = 10 , restraint n = 9 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA. g ) Kaolin clay intake (18-hrs) following tube restraint in WT (control n = 7 , restraint n = 7 ) and Gfral -/- mice (control n = 10 , restraint n = 9 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA. h ) Time in center and total distance during open-field test following GDF15 treatment with representative images showing movement of individual mice. n = 9 per group. Data presented as mean ± s.e.m. with p-values calculated using unpaired two-tail t-test. i ) Time in light during light-dark box test following vehicle ( n = 8 ) or GDF15 treatment ( n = 9 ). Data presented as mean ± s.e.m. with p-values calculated using unpaired two-tail t-test. j ) Daily chow food intake throughout repeated GDF15 (5 nM/kg IP). n = 12 per group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with post-hoc test and Tukey’s correction. k ) Time in the center during open-field test following GDF15 treatment (5 nM/kg IP) with representative images of movement of individual mice. n = 6 per group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA. Chr. GDF15: Chronic GDF15. l ) Total distance traveled during open-field test following GDF15 treatment (5 nM/kg IP) with representative images showing representative movement of individual mice. n = 6 per group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA. Chr. GDF15: Chronic GDF15.

    Journal: Nature Metabolism

    Article Title: GDF15 links adipose tissue lipolysis with anxiety

    doi: 10.1038/s42255-025-01264-3

    Figure Lengend Snippet: a ) Non-ambulatory movements, b ) Total physical activity, c ) Total food intake, d ) respiratory exchange ratio (RER), e ) Energy expenditure in WT (saline n = 4 , epinephrine n = 4 ) and Gfral -/- mice (saline n = 4 , epinephrine n = 4 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with post-hoc test and Tukey’s correction. f ) Chow intake (18-hrs) following tube restraint in WT (control n = 7 , restraint n = 7 ) and Gfral -/- mice (control n = 10 , restraint n = 9 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA. g ) Kaolin clay intake (18-hrs) following tube restraint in WT (control n = 7 , restraint n = 7 ) and Gfral -/- mice (control n = 10 , restraint n = 9 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA. h ) Time in center and total distance during open-field test following GDF15 treatment with representative images showing movement of individual mice. n = 9 per group. Data presented as mean ± s.e.m. with p-values calculated using unpaired two-tail t-test. i ) Time in light during light-dark box test following vehicle ( n = 8 ) or GDF15 treatment ( n = 9 ). Data presented as mean ± s.e.m. with p-values calculated using unpaired two-tail t-test. j ) Daily chow food intake throughout repeated GDF15 (5 nM/kg IP). n = 12 per group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with post-hoc test and Tukey’s correction. k ) Time in the center during open-field test following GDF15 treatment (5 nM/kg IP) with representative images of movement of individual mice. n = 6 per group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA. Chr. GDF15: Chronic GDF15. l ) Total distance traveled during open-field test following GDF15 treatment (5 nM/kg IP) with representative images showing representative movement of individual mice. n = 6 per group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA. Chr. GDF15: Chronic GDF15.

    Article Snippet: Recombinant human GDF15 (5 nM kg −1 ; Novo Nordisk) or vehicle was injected IP at ~09:00 (ref. ).

    Techniques: Activity Assay, Saline, Control

    a ) Quantification of c-Fos positive cells in the locus coeruleus 90-min following GDF15 treatment (5 nm/kg IP), with representative pictures of the staining for TH and c-Fos. n = 4 per group. Data presented as mean ± s.e.m. with p-values calculated using unpaired two-tail t-test. Scale bar=200 µm. 4 V: 4 th ventricle, LC: locus coeruleus, TH: tyrosine hydroxylase. b ) Quantification of c-Fos positive cells in the PFC and BLA 90-min following GDF15 treatment (5 nm/kg IP), with representative pictures of the staining. n = 4 per group. Data presented as mean ± s.e.m. with p-values calculated using unpaired two-tail t-test. Scale bar=200 µm. BLA: basolateral amygdala, cc: corpus callosum, mPFC: medial prefrontal cortex. c ) Serum GDF15 in WT (control n = 9 , restraint n = 9 ) and Gfral -/- mice (control n = 8 , restraint n = 8 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with Tukey’s post-hot correction. d ) Serum corticosterone in WT (control n = 4, CRH n = 6 ) and Gfral -/- mice (control n = 4 , CRH n = 6 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA at each timepoint. e ) Serum adrenocorticotropic hormone (ACTH) in WT (control n = 4, CRH n = 6 ) and Gfral -/- mice (control n = 4 , CRH n = 6 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA at each timepoint. f ) Serum corticosterone 6-hr post treatment with dexamethasone (Dexa, 100 µg/kg IP). n = 4 per group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA.

    Journal: Nature Metabolism

    Article Title: GDF15 links adipose tissue lipolysis with anxiety

    doi: 10.1038/s42255-025-01264-3

    Figure Lengend Snippet: a ) Quantification of c-Fos positive cells in the locus coeruleus 90-min following GDF15 treatment (5 nm/kg IP), with representative pictures of the staining for TH and c-Fos. n = 4 per group. Data presented as mean ± s.e.m. with p-values calculated using unpaired two-tail t-test. Scale bar=200 µm. 4 V: 4 th ventricle, LC: locus coeruleus, TH: tyrosine hydroxylase. b ) Quantification of c-Fos positive cells in the PFC and BLA 90-min following GDF15 treatment (5 nm/kg IP), with representative pictures of the staining. n = 4 per group. Data presented as mean ± s.e.m. with p-values calculated using unpaired two-tail t-test. Scale bar=200 µm. BLA: basolateral amygdala, cc: corpus callosum, mPFC: medial prefrontal cortex. c ) Serum GDF15 in WT (control n = 9 , restraint n = 9 ) and Gfral -/- mice (control n = 8 , restraint n = 8 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA with Tukey’s post-hot correction. d ) Serum corticosterone in WT (control n = 4, CRH n = 6 ) and Gfral -/- mice (control n = 4 , CRH n = 6 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA at each timepoint. e ) Serum adrenocorticotropic hormone (ACTH) in WT (control n = 4, CRH n = 6 ) and Gfral -/- mice (control n = 4 , CRH n = 6 ). Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA at each timepoint. f ) Serum corticosterone 6-hr post treatment with dexamethasone (Dexa, 100 µg/kg IP). n = 4 per group. Data presented as mean ± s.e.m. with p-values calculated using 2-way ANOVA.

    Article Snippet: Recombinant human GDF15 (5 nM kg −1 ; Novo Nordisk) or vehicle was injected IP at ~09:00 (ref. ).

    Techniques: Staining, Control

    Characteristics of obesity subjects according to MASLD and MetS

    Journal: Italian Journal of Pediatrics

    Article Title: Increased serum carboxylesterase-1 levels are associated with metabolic dysfunction associated steatotic liver disease and metabolic syndrome in children with obesity

    doi: 10.1186/s13052-024-01733-7

    Figure Lengend Snippet: Characteristics of obesity subjects according to MASLD and MetS

    Article Snippet: Serum levels of adiponectin, leptin, GDF15, IGF-1, CES1 were measured using enzyme-linked immunosorbent assay ELESA kits (Boster Biological, Pleasanton, CA) following the manufacturer’s protocol.

    Techniques:

    Correlation analysis between CES1 and obesity-related secreted proteins. ( A ) Adiponectin, ( B ) Leptin, ( C ) GDF15, ( D ) IGF-1. Spearman correlation coefficient was used. Statistical assessment was 2-sided and considered statistically significant at * P < 0.05, ** P < 0.01

    Journal: Italian Journal of Pediatrics

    Article Title: Increased serum carboxylesterase-1 levels are associated with metabolic dysfunction associated steatotic liver disease and metabolic syndrome in children with obesity

    doi: 10.1186/s13052-024-01733-7

    Figure Lengend Snippet: Correlation analysis between CES1 and obesity-related secreted proteins. ( A ) Adiponectin, ( B ) Leptin, ( C ) GDF15, ( D ) IGF-1. Spearman correlation coefficient was used. Statistical assessment was 2-sided and considered statistically significant at * P < 0.05, ** P < 0.01

    Article Snippet: Serum levels of adiponectin, leptin, GDF15, IGF-1, CES1 were measured using enzyme-linked immunosorbent assay ELESA kits (Boster Biological, Pleasanton, CA) following the manufacturer’s protocol.

    Techniques:

    a , b , Change in body weight ( a ) and food intake ( b ) of 26–28-week-old male DIO C57BL/6J mice following 7 days of treatment with the indicated dose of N -acetyltaurine (NAT; i.p.). For saline versus N -acetyltaurine (15 mg per kg per day), P = 5.95 × 10 –4 ; for saline versus N -acetyltaurine (50 mg per kg per day), P = 6.3 × 10 –4 . N = 5 per group for vehicle, 1 and 5 mg per kg per day; N = 6 per group for 15 and 50 mg per kg per day. c , d , Change in body weight ( c ) and food intake ( d ) of 19–21-week-old male DIO C57BL/6J mice following treatment with the indicated metabolite at a dose of 15 mg per kg per day (i.p.). N = 5 per group. e – g , Western blots with anti-PTER (top) and anti-tubulin (bottom) antibodies ( e ), N -acetyltaurine hydrolysis activity ( f ) and tissue N -acetyltaurine levels ( g ) from cortex (Cort.), hypothalamus (Hyp.) and brainstem (BS) of WT mice and Pter KO mice. For WT versus Pter KO brainstem, P = 6.65 × 10 –4 . N = 6 per group for f and g . h , Change in 24-h food intake of 6-month-old male DIO mice treated with a single dose of GDF15 (0.1 mg kg –1 , i.p.) in the presence of anti-GFRAL antibody (10 mg kg –1 , i.p.) or IgG control antibody (10 mg kg –1 , i.p.). N = 5 per group. i , j , Change in body weight ( i ) and cumulative food intake ( j ) of 16-week-old male DIO mice following saline or N -acetyltaurine (15 mg per kg per day, i.p.) treatment and with IgG or anti-GFRAL antibody co-treatment (10 mg kg –1 , i.p., once every 3 days). N = 10 per group. Data are shown as the mean ± s.e.m. For e , the loading control was performed on the same blot. In a – d and f – h , P values were calculated from two-tailed unpaired t -tests and were not corrected for multiple comparisons. In i and j , P values were calculated from two-way ANOVA with post hoc Sidak’s multiple comparisons test. All experiments were performed once.

    Journal: Nature

    Article Title: PTER is a N -acetyltaurine hydrolase that regulates feeding and obesity

    doi: 10.1038/s41586-024-07801-6

    Figure Lengend Snippet: a , b , Change in body weight ( a ) and food intake ( b ) of 26–28-week-old male DIO C57BL/6J mice following 7 days of treatment with the indicated dose of N -acetyltaurine (NAT; i.p.). For saline versus N -acetyltaurine (15 mg per kg per day), P = 5.95 × 10 –4 ; for saline versus N -acetyltaurine (50 mg per kg per day), P = 6.3 × 10 –4 . N = 5 per group for vehicle, 1 and 5 mg per kg per day; N = 6 per group for 15 and 50 mg per kg per day. c , d , Change in body weight ( c ) and food intake ( d ) of 19–21-week-old male DIO C57BL/6J mice following treatment with the indicated metabolite at a dose of 15 mg per kg per day (i.p.). N = 5 per group. e – g , Western blots with anti-PTER (top) and anti-tubulin (bottom) antibodies ( e ), N -acetyltaurine hydrolysis activity ( f ) and tissue N -acetyltaurine levels ( g ) from cortex (Cort.), hypothalamus (Hyp.) and brainstem (BS) of WT mice and Pter KO mice. For WT versus Pter KO brainstem, P = 6.65 × 10 –4 . N = 6 per group for f and g . h , Change in 24-h food intake of 6-month-old male DIO mice treated with a single dose of GDF15 (0.1 mg kg –1 , i.p.) in the presence of anti-GFRAL antibody (10 mg kg –1 , i.p.) or IgG control antibody (10 mg kg –1 , i.p.). N = 5 per group. i , j , Change in body weight ( i ) and cumulative food intake ( j ) of 16-week-old male DIO mice following saline or N -acetyltaurine (15 mg per kg per day, i.p.) treatment and with IgG or anti-GFRAL antibody co-treatment (10 mg kg –1 , i.p., once every 3 days). N = 10 per group. Data are shown as the mean ± s.e.m. For e , the loading control was performed on the same blot. In a – d and f – h , P values were calculated from two-tailed unpaired t -tests and were not corrected for multiple comparisons. In i and j , P values were calculated from two-way ANOVA with post hoc Sidak’s multiple comparisons test. All experiments were performed once.

    Article Snippet: Recombinant GDF15 (957-GD) was purchased from R&D Systems.

    Techniques: Saline, Western Blot, Activity Assay, Control, Two Tailed Test

    Related to Fig. . a - d , Body weight ( a , b ) and food intake ( c , d ) of 6 to 7-month-old DIO male C57BL/6J mice after a 7-day treatment of saline or N-acetyltaurine (15 mg/kg/day, IP) or GLP-1 (2 mg/kg/day, IP) with or without Exendin-3 (0.1 mg/kg/day, IP). N = 7/group. NAT, N-acetyltaurine. e , f , Body weight ( e ) and food intake ( f ) of 5-month-old DIO male C57BL/6J mice or 3 to 4-month-old MC4R-KO mice on high fat diet after a 7-day treatment of saline or N-acetyltaurine (15 mg/kg/day, IP). N = 6/group. NAT, N-acetyltaurine. g , Plasma GDF15 (left), GLP-1 (middle) and leptin (right) levels of 19 to 21-week-old male DIO C57BL/6J mice following treatment with N-acetyltaurine 15 mg/kg/day (IP) or saline. N = 5 per group. NAT, N-acetyltaurine. Data are shown as mean ± SEM. P-values were calculated from two-tailed unpaired t-tests.

    Journal: Nature

    Article Title: PTER is a N -acetyltaurine hydrolase that regulates feeding and obesity

    doi: 10.1038/s41586-024-07801-6

    Figure Lengend Snippet: Related to Fig. . a - d , Body weight ( a , b ) and food intake ( c , d ) of 6 to 7-month-old DIO male C57BL/6J mice after a 7-day treatment of saline or N-acetyltaurine (15 mg/kg/day, IP) or GLP-1 (2 mg/kg/day, IP) with or without Exendin-3 (0.1 mg/kg/day, IP). N = 7/group. NAT, N-acetyltaurine. e , f , Body weight ( e ) and food intake ( f ) of 5-month-old DIO male C57BL/6J mice or 3 to 4-month-old MC4R-KO mice on high fat diet after a 7-day treatment of saline or N-acetyltaurine (15 mg/kg/day, IP). N = 6/group. NAT, N-acetyltaurine. g , Plasma GDF15 (left), GLP-1 (middle) and leptin (right) levels of 19 to 21-week-old male DIO C57BL/6J mice following treatment with N-acetyltaurine 15 mg/kg/day (IP) or saline. N = 5 per group. NAT, N-acetyltaurine. Data are shown as mean ± SEM. P-values were calculated from two-tailed unpaired t-tests.

    Article Snippet: Recombinant GDF15 (957-GD) was purchased from R&D Systems.

    Techniques: Saline, Two Tailed Test